Post by Regeneron

Today we announced positive data from our Phase 3 trial evaluating our investigational siRNA therapeutic in generalized myasthenia gravis (#gMG) were published in The Lancet Group and presented at the American Academy of Neurology Annual Meeting.    Learn more about our novel approach and these important findings. 🧠 https://bit.ly/4tSNh3A    #AAN2026